1. Efficacy and safety of tribendimidine against Opisthorchis viverrini: two randomised, parallel-group, single-blind, dose-ranging, phase 2 trials 
Somphou Sayasone, PhD, Peter Odermatt, PhD, Youthanavanh Vonghachack, MD, Syda Xayavong, MD, Kanpaseuth Senggnam, MD, Urs Duthaler, PhD, Kongsap Akkhavong, MD, Jan Hattendorf, PhD, Prof Jennifer Keiser, PhD 
The Lancet Infectious Diseases 
Volume 16, Issue 10, Pages (October 2016)
DOI: /S (16)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profiles
Flow charts for enrolment of adolescents and adults (A [study 1], B [study 2]) and children (C).
The Lancet Infectious Diseases  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Figure 2 Cure rates in adolescents and adults (N=310)
Circles show observed cure rates with 95% CIs (vertical lines). Numbers in the circles show geometric mean infection intensities at baseline. Dashed lines represent the estimated dose–response curve and corresponding 95% CIs predicted by the Emax models. epg=eggs per g of stool.
The Lancet Infectious Diseases  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

4. Figure 3 Cure rates in children (N=167)
Circles show observed cure rates with 95% CIs (vertical bars). Numbers in the circles show geometric mean infection intensities at baseline. Dashed lines represent the estimated dose–response curve and corresponding 95% CIs predicted by the Emax model (only observations from study 1). epg=eggs per g of stool.
The Lancet Infectious Diseases  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions